Amaç: Karbon kaplı boncuklar (Durasphere®) ve dekstranomer/hiyalüronik asit kopolimeri (Deflux®) ile primer grade I-III primer vezikoüreteral reflü (VUR) nedeni ile endoskopik subüreterik enjeksiyon yapılan erişkin kadın hastaları retrospektif olarak değerlendirdik. Gereç ve Yöntemler: İzmir Kâtip Çelebi Üniversitesi Tıp Fakültesi ve Niğde Ömer Halisdemir Üniversitesi Tıp Fakültesinin üroloji bölümlerinde, primer grade I-III VUR nedeni ile endoskopik subüreteral enjeksiyon yapılan kadınların tıbbi kayıtları retrospektif olarak gözden geçirildi. Nörojenik mesaneye sekonder VUR, infravezikal obstrüksiyon, mesane tümörünün rezeksiyonu, üreterosel insizyonu veya üreteral reimplantasyonu olan ve 18 yaşın altındaki hastalar çalışma dışı bırakıldı. Bulgular: Durasphere® grubu; preoperatif grade II ve III VUR sırasıyla 7 ve 8 üreterde tespit edildi. Üç hastada bilateral VUR vardı. Cinsel olarak aktif 10 ve tekrarlayan üriner enfeksiyonu olan 7 hasta mevcuttu. Doğum yapan 7 hastanın 6'sında, gebelik sırasında hastaneye yatırılması gereken piyelonefrit öyküsü vardı. Ortalama 38,00±14,70 aylık takip periyodunda vezikoüreteral obstrüksiyon gözlenmedi, ancak 2 olguda VUR nüksüne bağlı ikinci endoskopik girişim, 1 hastaya Cohen üreteroneosistostomi yapıldı. Deflux® grubu; On dört hastanın 3'ünde bilateral VUR vardı. Grade I, II ve III reflü, sırasıyla 3, 8 ve 6 böbrek ünitesinde izlendi. Hastaların 13'ü cinsel olarak aktif olup, 11'inde doğum öyküsü, 6'sında tekrarlayan idrar yolu enfeksiyonu, 4'ünde gebelik sırasında piyelonefrit nedeni ile hastanede yatış öyküsü vardı. Dört hastaya, başarısızlık nedeni ile ikinci endoskopik subüreterik enjeksiyon uygulandı. Gruplarda postoperatif piyelonefrit izlenmedi. Sonuç: Karbon kaplı boncuklar güvenli, uygulanabilir, etkili subüreterik hacim artırıcı maddedir ve erişkin kadın popülasyonunda ciddi dilatasyon olmayan reflüksif üreterlerinin endoskopik tedavisinde Deflux® ile karşılaştırılabilir sonuçlara sahiptir.
Anahtar Kelimeler: Deflux®; Durasphere®; kadın; vezikoüreteral reflü
Objective: We retrospectively evaluated adult female patients who received endoscopic subureteric injection due to carboncoated beads (Durasphere®) and dextranomer/hyaluronic acid copolymer (Deflux®) with primary grade I-III primary vesicoureteral reflux (VUR). Material and Methods: Medical records of women who underwent endoscopic suburethral injection due to primary grade I-III VUR in the urology departments of İzmir Kâtip Çelebi University Faculty of Medicine and Niğde Ömer Halisdemir University Faculty of Medicine were retrospectively reviewed. Patients with secondary VUR to neurogenic bladder, infravesical obstruction, bladder tumor resection, ureterocele incision or ureteral reimplantation, and being under 18 years of age were excluded from the study. Results: Durasphere® group; preoperative grade-II and III VUR were detected in 7 and 8 ureters, respectively. Three patients had bilateral VUR. There were 10 sexually active and 7 patients with recurrent urinary infections. Six of 7 delivered patients had a history of hospitalization during pregnancy due to pyelonephritis. In 38,00±14,70 months follow-up period, there was no vesicoureteral obstruction, but 2 cases needed second endoscopic intervention for VUR recurrence, 1 underwent Cohen ureteroneocystostomy. Deflux® group; three of 14 patients had bilateral VUR. Grade I, II and III reflux was observed in 3, 8 and 6 units, respectively. Thirteen patients were sexually active, 11 were delivered, 6 had recurrent urinary tract infections, and 4 had history of hospitalization for pyelonephritis during pregnancy. Four patients underwent second endoscopic subureteric injection for failure. Postoperative pyelonephritis was not observed in the groups. Conclusion: Carbon coated beads are safe, feasible, effective subureteric bulking agent and have comparable results with Deflux® in the endoscopic treatment of reflux ureters without serious dilatation in the adult female population.
Keywords: Deflux®; Durasphere®; female; vesicoureteral reflux
- Arce J, Angerri O, Caffaratti J, Garat JM, Villavicencio H. Efficiency of endoscopic treatment for vesico-ureteric reflux in adults. BJU Int. 2009;103(1):71-4. [Crossref] [PubMed]
- Tekgül S, Reidmiller H, Hoebeke P, Kočvara R, Nijman RJM, Radmayr C, et al; European Association of Urology. EAU guidelines on vesicoureteral reflux in children. Eur Urol. 2012;62(3):534-42. [Crossref] [PubMed]
- Peters CA, Skoof SJ, Arant Jr. BS, Copp HL, Elder JS, Hudson RG, et al. Summary of the AUA Guideline on management of primary vesicoureteral reflux in children. J Urol. 2010;183(3):1134-44. [Crossref] [PubMed]
- Köhler J, Thysell H, Tencer J, Forsberg L, Hellström M. Concervative treatment and anti-reflux surgery in adults with vesico-ureteral reflux: effect on urinary tract infections, renal function and loin pain in a long term follow-up study. Nephrol Dial Transplant. 2001;16(1):52-60. [Crossref] [PubMed]
- Smellie JM, Prescod NP, Shaw PJ, Risdon RA, Bryant TN. Childhood reflux and urinary infection: a follow-up of 10-41 years in 226 adults. Pediatr Nephrol. 1998;12(9):727-36. [Crossref] [PubMed]
- Barai S, Bandopadhayaya GP, Bhowmik D, Patel CD, Malhotra A, Agarwal P, et al. Prevalence of vesicoureteral reflux in patients with incidentally diagnosed adult hypertension. Urology. 2004;63(6):1045-8. [Crossref] [PubMed]
- Hollowell JG. Outcome of pregnancy in women with in women with a history of vesico-ureteric reflux. BJU Int. 2008;102(7):780-4. [Crossref] [PubMed]
- Austin JC. Treatment of vesicoureteral reflux after puberty. Adv Urol. 2008;2008:590185. [Crossref] [PubMed] [PMC]
- Läckgren G, Wåahlin N, Sköldenberg E, Stenberg A. Long term follow-up of children treated with dextranomer/hyaluronic acid copolymer for vesicoureteral reflux. J Urol. 2001;166(5):1887-92. [Crossref] [PubMed]
- Medical versus surgical treatment of primary vesicoureteral reflux: report of the International Reflux Study Committee. Pediatrics. 1981;67(3):392-400. [PubMed]
- O'Donnell B, Puri P. Treatment of vesicoureteral reflux by endoscopic injection of Teflon. Br Med J (Clin Res Ed). 1984;289(6436):7-9. [Crossref] [PubMed] [PMC]
- Choo MS, Hong B, Ji YH, Chung H, Choe JH, Park WH, et al. Endoscopic treatment of vesicoureteral reflux with polydimethylsiloxane in adult women. Eur Urol. 2004;45(6):787-9. [Crossref] [PubMed]
- Pichler R, Heidegger I, Schlenck B, Horninger W, Oswald J. Clinical outcome after endoscopic therapy for occult vesicoureteral reflux in females: preliminary results of a retrospective case series. Scand J Urol. 2014;48(4):387-92. [Crossref] [PubMed]
- Hill JB, Sheffield JS, McIntire DD, Wendel Jr. GD. Acute pyelonephritis in pregnancy. Obstet Gynecol. 2005;105(1):18-23. [Crossref] [PubMed]
- Glaser AP, Schaeffer AJ. Urinary tract infection and bacteriuria in pregnancy. Urol Clin North Am. 2015;42(4):547-60. [Crossref] [PubMed]
- Murphy AM, Ritch CR, Reiley EA, Hensle TW. Endoscopic management of vesicoureteral reflux in adult women. BJU Int. 2011;108(2):252-4. [Crossref] [PubMed]
- Moore K, Bolduc S. Treatment of vesicoureteral reflux in adults by endoscopic injection. Urology. 2011;77(6):1284-7. [Crossref] [PubMed]
- Natsheh A, Shenfeld OZ, Farkas A, Chertin B. Endoscopic treatment of vesicoureteral reflux in an adult population: can we teach our adult urology collegues? J Pediatr Urol. 2010;6(6):600-4. [Crossref] [PubMed]
- Okeke Z, Fromer D, Katz MH, Reiley EA, Terry W, Hensle TW. Endoscopic management of vesicoureteral reflux in women presenting with pyelonephritis. J Urol 2006;176(5):2219-21. [Crossref] [PubMed]
- Zilberman DE, Mor Y. Has the data efflux regarding the promising outcome following injection of deflux changed the management of adult vesicoureteral reflux? Adv Urol. 2008;2008:361324. [Crossref] [PubMed] [PMC]
- Valdersteen DR, Routh JC, Kirsch AJ, Scherz HC, Ritchey ML, Shapiro E, et al. Postoperative ureteral obstruction after subureteral injection of dextranomer/hyaluronic acid copolymer. J Urol. 2006;176(4 Pt 1):1593-5. [Crossref] [PubMed]
- Tsai CC, Lin V, Tang L. Injectable biomaterials for incontinence and vesico-ureteral reflux: current status and future promise. J Biomed Mater Res B Appl Biomater. 2006;77B(1):177-8. [Crossref] [PubMed]
- Kirsch AJ. Injection therapy for reflux: why it works and why it fails. J Urol. 2012;188(1):16-7. [Crossref] [PubMed]
- Toia B, Gresty H, Pakzad M, Hamid R, Ockrim J, Greenwell T. Bulking for stress urinary incontinence in men: a systematic review. Neurourol Urodyn. 2019;38(7):1804-11. [Crossref] [PubMed]
- Pannek J, Brands FH, Senge T. Particle migration after transurethral injection of carbon coated beads for stres urinary incontinence. J Urol. 2001;166(4):1350-3. [Crossref] [PubMed]
- Altomare DF, La Torre F, Rinaldi M, Binda GA, Pescatori M. Carbon-coated microbeads anal injection in outpatient treatment of minor fecal incontinence. Dis Colon Rectum. 2008;51(4):432-5. [Crossref] [PubMed]
- Ozkuvanci U, Donmez MI, Ozgor F, Erbin A, Pasin Ö, Muslumanoglu AY. Durasphere® EXP: a non-biodegradable agent for treatment of primary vesico-ureteral reflux in children. Int Braz J Urol. 2018;44(3):585-90. [Crossref] [PubMed] [PMC]
- Antonopoulos IM, Piovesan AC, Falci Jr. R, Kanashiro H, Saito FJA, Nahas WC. Transurethral injection therapy with carbon-coated beads (Durasphere®) for treatment of recurrent pyelonephritis in kidney transplant patients with vesico-ureteral reflux to the allograft. Clin Transplant. 2011;25(2):329-33. [Crossref] [PubMed]
.: Process List